Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPETE-2: PFO Closure for Migraine
NCT05561660Phase 4Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoints: Responder rate at 12 months and Treatment safety at 12 months. Status: unknown.
Beyond the preview
Go deeper on NCT05561660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561660.